FDA批准 Vimseltinib 治疗成人的乳房巨型细胞肿瘤, 带来新的希望。 FDA approves vimseltinib for treating tenosynovial giant cell tumors in adults, offering new hope.

林业发展局已核准Vimseltinib(Romvimza)治疗无法接受外科手术的有症状的乳房巨型细胞肿瘤(TGCT)的成年人。 The FDA has approved vimseltinib (Romvimza) for treating adults with symptomatic tenosynovial giant cell tumors (TGCT) who cannot undergo surgery. 该药物是CSF1R阻塞剂,在试验中发现有40%的响应率,大大改善了病人的运动范围,减轻了疼痛,没有严重的副作用。 The drug, a CSF1R blocker, was found to have a 40% response rate in trials, significantly improving patients' range of motion and reducing pain without severe side effects. 这一批准为患有这种罕见、无癌肿瘤的病人提供了新的希望。 This approval offers new hope for patients with this rare, noncancerous tumor.